Skip to main content
World Journal of Gastroenterology logoLink to World Journal of Gastroenterology
. 2015 Jan 21;21(3):878–887. doi: 10.3748/wjg.v21.i3.878

Hes1, an important gene for activation of hepatic stellate cells, is regulated by Notch1 and TGF-β/BMP signaling

Kai Zhang 1,2,3, Yan-Qiong Zhang 1,2,3, Wen-Bing Ai 1,2,3, Qing-Ting Hu 1,2,3, Qiao-Juan Zhang 1,2,3, Lin-Yan Wan 1,2,3, Xiao-Lian Wang 1,2,3, Chang-Bai Liu 1,2,3, Jiang-Feng Wu 1,2,3
PMCID: PMC4299340  PMID: 25624721

Abstract

AIM: To determine the role of Notch1 and Hes1 in regulating the activation of hepatic stellate cells (HSCs) and whether Hes1 is regulated by transforming growth factor (TGF)/bone morphogenetic protein (BMP) signaling.

METHODS: Immunofluorescence staining was used to detect the expression of desmin, glial fibrillary acidic protein and the myofibroblastic marker α-smooth muscle actin (α-SMA) after freshly isolated, normal rat HSCs had been activated in culture for different numbers of days (0, 1, 3, 7 and 10 d). The expression of α-SMA, collagen1α2 (COL1α2), Notch receptors (Notch1-4), and the Notch target genes Hes1 and Hey1 were analyzed by reverse transcriptase-polymerase chain reaction. Luciferase reporter assays and Western blot were used to study the regulation of α-SMA, COL1α1, COL1α2 and Hes1 by NICD1, Hes1, CA-ALK3, and CA-ALK5 in HSC-T6 cells. Moreover, the effects of inhibiting Hes1 function in HSC-T6 cells using a Hes1 decoy were also investigated.

RESULTS: The expression of Notch1 and Hes1 mRNAs was significantly down-regulated during the culture of freshly isolated HSCs. In HSC-T6 cells, Notch1 inhibited the promoter activities of α-SMA, COL1α1 and COL1α2. On the other hand, Hes1 enhanced the promoter activities of α-SMA and COL1α2, and this effect could be blocked by inhibiting Hes1 function with a Hes1 decoy. Furthermore, co-transfection of pcDNA3-CA-ALK3 (BMP signaling activin receptor-like kinase 3) and pcDNA3.1-NICD1 further increased the expression of Hes1 compared with transfection of either vector alone in HSC-T6 cells, while pcDNA3-CA-ALK5 (TGF-β signaling activin receptor-like kinase 5) reduced the effect of NICD1 on Hes1 expression.

CONCLUSION: Selective interruption of Hes1 or maintenance of Hes1 at a reasonable level decreases the promoter activities of α-SMA and COL1α2, and these conditions may provide an anti-fibrotic strategy against hepatic fibrosis.

Keywords: Hes1, Notch1, TGF-β/BMP, Hepatic stellate cells, Hepatic fibrosis


Core tip: In our paper, we found that Notch signaling appears to crosstalk with TGF-β/BMP signaling and co-regulates the expression of Hes1 in hepatic stellate cells. Notch1 may keep Hes1 protein in a reasonable range due to Hes1 auto-negative feedback, allowing Notch1 to repress the expression of α-SMA and collagen1α2 (COL1α2). Over-expression of Hes1 via transfection, thus lacking the negative feedback, enhances the promoter activities of α-smooth muscle actin (α-SMA) and COL1α2, consistent with the finding when Hes1 is captured by a Hes1-decoy oligodeoxynucleotide. This may provide an anti-fibrotic strategy against hepatic fibrosis. Further investigations in the future on the molecular mechanism by which Hes1 regulates the expression of α-SMA and COL1α2 should provide additional support for such an approach.

INTRODUCTION

The activation of hepatic stellate cells (HSCs), a key step in liver fibrosis, can lead to the development of myofibroblast-like cells and contribute to liver fibrosis[1]. The main characteristics of the formation of myofibroblast-like cells are the expression of α-smooth muscle actin (α-SMA) and extracellular matrix (ECM) proteins, particularly collagen I[2]. Because of the importance of myofibroblasts in liver fibrosis, the majority of antifibrotic therapies are designed to inhibit the formation of myofibroblastic cells[3].

Previous studies have revealed that the transforming growth factor-β (TGF-β)/bone morphogenetic protein (BMP) signaling pathway is a pivotal player in the activation of HSCs[4,5]. TGF-β is a key mediator in the activation of HSCs[6]. BMPs are also members of the TGF-β superfamily and are antagonistic against TGF-β[7].

Notch signaling is an evolutionarily conserved pathway controlling diverse aspects of development and disease[8]. In mammals, the Notch family contains five Notch ligands (Jagged1, Jagged2, Delta-like1, Delta-like3, and Delta-like4) and four Notch receptors (Notch1-4). Among the Notch target genes are the basic helix-loop-helix (bHLH) transcription factors of the Hes (Hairy-Enhancer of Split) and HERP (Hes-related repressor protein) families, which function as transcriptional repressors[9,10].

During hematopoiesis and immune development, Notch is critical for T/B lineage specification and for the generation of splenic marginal zone B cells[11,12]. Earlier research has mainly focused on the interconnections between Notch and hematopoiesis or immune system-related molecules, aiming to find a preferable method to modulate hematopoiesis or treat immune disorders.

Recently, several studies have implicated Notch signaling in some human fibrosis diseases, such as renal, pulmonary and even liver fibrosis[13,14]. Evidence suggests that TGF-β/BMP signaling, as a key mediator in the process of HSC activation, has a synergistic effect with Notch in many cell types, enhancing the expression of target genes[15,16]. While the Jagged/Notch pathway may selectively mediate the fibrogenic properties of TGF-β1, which are essential to promote the production and deposition of the ECM[17,18], whether Notch signaling regulates TGF-β/BMP in HSCs remains largely unclear.

We hypothesized that Notch signaling can interact with TGF-β/BMP signaling and play a role in HSC activation. To test this hypothesis, we investigated the relationship between the activation of HSCs and Notch signaling pathways. Our findings demonstrate a pivotal role for Notch signaling in this process.

MATERIALS AND METHODS

HSC preparation and HSC-T6 cell line

The use of animals for this study was approved by the laboratory animal center of China, Three Gorges University. Primary rat HSCs were isolated using a previously described method with minor modifications[19]. Freshly isolated, normal rat HSCs were cultured on 6- or 24-well plates in low glucose DMEM (Invitrogen) supplemented with 10% FBS and antibiotics for 0, 1, 3, 7, or 10 d to examine the quiescent, activating, or fully activated cells. HSC-T6 cells, an immortalized rat HSC line provided by the institute of liver disease at Shanghai University of Traditional Chinese Medicine, were cultured in low glucose DMEM supplemented with 10% FBS.

Western blot analysis

Cells were lysed in lysis buffer (25 mmol/L Tris-HCl pH 7.5, 2.5 mmol/L EDTA, 137 mmol/L NaCl, 2.7 mmol/L KCl, 1% sodium deoxycholic acid, 0.1% SDS, 1% TritonX-100, and 2 mmol/L PMSF) and protease inhibitor cocktail for 30 min at 4 °C. The cell lysates were clarified by centrifugation at 12000 rpm for 20 min at 4 °C, and the supernatants were collected. The protein concentrations were measured using a BCA Protein Assay kit (Thermo). An equal amount of protein from each sample was separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a polyvinylidene difluoride membrane. The membrane was incubated with a mouse monoclonal anti-α-SMA antibody (1:1000 dilution) (Sigma), a goat polyclonal anti-Hes1 antibody (1:1000 dilution) (SANTA CRUZ), a rabbit polyclonal anti-TGF-β(R) antibody (1:1000 dilution) (SANTA CRUZ), a mouse monoclonal anti-HA antibody (1:3000 dilution) (Abmart), a mouse monoclonal anti-c-myc antibody (1:3000 dilution) (Abmart) or a mouse monoclonal anti-β-actin antibody (1:3000 dilution) (Sigma) for 24 h at 4 °C. This primary antibody incubation was followed by incubation with HRP-conjugated anti-mouse (1:3000 dilution), anti-rabbit (1:3000 dilution) or anti-goat (1:12000 dilution) antibody as the secondary antibody for 1 h at RT. These membranes were developed using Immobilon Western Detection Reagents (Millipore) according to the manufacturer’s instructions. The chemiluminescence on the membrane was detected using the VersaDoc system (Bio-Rad). Densitometric analyses of the band intensities were performed using ImageJ software (version 1.38 ×; National Institutes of Health).

RNA extraction and reverse transcriptase-polymerase chain reaction

Total RNA from freshly isolated HSCs or HSC-T6 cells was extracted using TRIzol reagent (Axygen). The RNA (2 mg) was reverse transcribed using a Transcriptor First Strand cDNA Synthesis Kit according to the manufacturer’s instructions (Fermentas). The primers used in the polymerase chain reaction (PCR) reactions to detect the mRNA levels were synthesized by Sangon Biotech (Shanghai, China) and are described in Table 1.

Table 1.

Primers for reverse transcriptase-polymerase chain reaction

Gene Forward primer Reverse primer Bp Accession No.
Notch1 AGAGCTTTTCCTGTGTCTGTCC CGGTACAGTCAGGTGTGTTGTT 414 NM_001105721
Notch2 GACTGCCAATACTCGACCTC TTCAGAAGTGAAGTCTCCAG 438 NM_024358.1
Notch3 CCTCTTTCACCTGTACCTGTCC ACACAGTAGTGGGAGTGGTCCT 496 NM_020087
Notch4 CAACTCTGCGAGAACGGTGG TGGAAGGAGCCCAAGGTGTT 443 NM_001002827.1
hes1 GCCAGCTGATATAATGGA TAGGTCATGGCGTTGATC 462 NM_024360.3
hey1 CTACAGCTCCTCTGATAGTG GAGGCATCGAGTCCTTCAAT 420 NM_001191845
TGF-β1 GGTGAAACGGAAGCGCATCG CTTGAATCTCTGCAGGCGCA 364 NM_021578.2
E-cadherin CTCGTGGCTTTGTCAGCA GACCCAGTCTCGTTTCTG 432 NM_031334.1
α-SMA GTGTGAAGAGGAAGACAG TTGGCCTTAGGGTTCAGC 348 NM_031004.2
β-catenin CTGACAGAGTTGCTCCACTC CAGCCCATCAACTGGATAGT 342 NM_053357.2
Bmp7 CAGAGCATCAACCCCAAGTT GATGAAGTGAACCAGTGTCT 396 NM_001191856.1
COL1α2 ACCTCAGGGTGTTCAAGGTG CGGATTCCAATAGGACCAGA 222 NM_053356
GAPDH ACCACAGTCCATGCCATCAC TCCACCACCCTGTTGCTGTA 480 NM_017008.4

Immunofluorescence analysis

Freshly isolated, normal rat HSCs cultured for varying lengths of time (1, 3, 7, 10 d) were fixed in phosphate buffered saline containing 4% paraformaldehyde at room temperature for 30 min and were then treated with blocking solution containing 0.1% Triton X-100. The fixed and blocked cells were incubated for 1 h with either a mouse monoclonal anti-α-SMA (1:100) (Sigma), a mouse monoclonal anti-GFAP (1:250) (Sigma) or a mouse monoclonal anti-desmin (1:600) (Sigma) antibody in 3% NCBS. The cells were then incubated with a Cy3-conjugated anti-mouse secondary antibody (1:1000) (NovoGene) for 1 h at 37 °C. After incubation, the cells were stained with the nuclear stain 4’,6-diamidino-2-phenyl-indole (DAPI). The cells were then examined under a fluorescence microscope (Nikon, Japan).

Constructs, transfection and luciferase reporter assay

The pcDNA3-CA-ALK3 (BMP signaling activin receptor-like kinase 3)[20] and pcDNA3-CA-ALK5 (TGF-β signaling activin receptor-like kinase 5)[21] plasmids were gifts from Professor Miyazono at Tokyo University. The rat Notch1 intracellular domain (NICD1) and Hes1 cDNA (Hes1) were cloned into the pcDNA3.1(+) vector. The promoters of α-SMA (pSMA), COL1α1 (P-COL1α1), COL1α2 (P-COL1α2) and Hes1 (P-Hes1) were cloned into the pGLuc-Basic vector (N8082S, NEB, United States) for luciferase assays. The HSC-T6 cells were seeded in a 24- or 6-well plate at 60% confluence. After 24 h, the cells were transfected with different plasmids using the FuGENE HD Transfection Reagent (Roche) according to the manufacturer’s instructions. The cells were lysed after 36 h in culture for Western blot analyses. For luciferase assays, the supernatants were collected 24 h after transfection, and the assays were performed using the Gaussia Luciferase Assay Kit (BioLux) according to the manufacturer’s instructions. The reactions were examined using a Fluorescence Detector (Brethold).

Synthesis of oligodeoxynucleotides and selection of sequence targets

The Hes1 oligodeoxynucleotide (ODN) decoy (5’-TTT CAC GAG TTT TCA CGA GTT T-3’, 5’-AAA CTC GTG AAA ACT CGT GAA A-3’) and scrambled (Scr) ODN decoy (5’-TTT ACA GAG TTT TAC AGA GTT T-3’, 5’- AAA CTC TGT AAA ACT CTG TAA A-3’) were synthesized by Sangon Biotech (Shanghai, China). These ODN decoys were annealed overnight while the temperature decreased from 80 °C to 25 °C. After GLuc reporter plasmids were transfected into HSC-T6 cells for 12 h, the Hes1 ODN decoy was delivered by Mirus (Mirus Bio Corporation). The supernatant was collected for luciferase reporter analysis after 24 h of culture.

Statistical analysis

Data are presented as mean ± SE of several experiments. The statistical significance was assessed using a two-tailed Student’s t-test. P < 0.05 was considered statistically significant.

RESULTS

Expression of Notch1 and Hes1 is reduced in activated HSCs

The activation of HSCs can be modeled in vitro by culturing freshly isolated (quiescent) rodent or human HSCs on plastic in serum-containing media. Freshly isolated HSCs from normal rats were cultured for various lengths of time (1, 3, 7 and 10 d), and the results showed that the HSCs lost their typical lipid droplets and developed into myofibroblast-like cells during culture (Figure 1A). When various HSC markers were analyzed by immunofluorescence, the expression of the HSC marker GFAP had decreased, desmin synthesis had increased, and the myofibroblast marker α-SMA had also increased (Figure 1B). To further characterize the quiescent and activated HSCs, we analyzed the expression of α-SMA, COL1α2, E-cadherin, TGF-β1, BMP7, and β-catenin on different days during the culture period (0, 1, 3, 7, and 10 d) by RT-PCR. The results showed that the mRNA levels of TGF-β1, BMP7 and β-catenin did not change during the activation of HSCs; the mRNA levels of E-cadherin, a marker of epithelial-mesenchymal transition (EMT), decreased, while the mRNA levels of the hepatic fibrosis-related genes α-SMA and COL1α2 increased (Figure 1C). We also used RT-PCR to analyze the expression of the Notch receptors (Notch1-4) and their target genes Hes1 and Hey1 on different days during the culture period. The mRNA levels of the Notch1 receptor decreased during culture, while the mRNA levels of the other Notch receptors (Notch2-4) changed inconsistently (Figure 1E). The mRNA levels of the Notch target gene Hes1 decreased, but the protein did not significantly change (Figure 1D).

Figure 1.

Figure 1

Characteristics of quiescent and activated hepatic stellate cells. A: Microscopic pictures of freshly isolated hepatic stellate cells (HSCs) after 1, 3, 7 and 10 d of culture; B: The expression of α-smooth muscle actin (α-SMA), desmin and GFAP detected by immunofluorescence staining. Red fluorescence represents α-SMA in pictures a, b, c, and d; desmin in pictures e, f, g, and h; and GFAP in pictures i, j, k, and l. The cell nuclei were visualized by DAPI (4, 6-diamidino-2-phenylindole) staining (blue). C: Expression analysis of collagen1α2, α-SMA, E-cadherin, transforming growth factor-β1 (TGFβ1), bone morphogenetic protein-7 (BMP7), and β-catenin in the cells in (A) measured by RT-PCR. RT-PCR of Gapdh served as a control; D: Analysis of α-SMA, Hes1 and TGF-β (R) by Western blotting of the cells in (A). The β-actin protein served as a control; E: RT-PCR analysis of Notch receptors (Notch1-4) and the Notch target genes Hes1 and Hey1. Notably, the data for Hes1 in D and E do not agree with each other.

Over-expression of Notch1 decreases the expression of myofibroblastic markers in HSC-T6 cells

To investigate the role of Notch1 on the activation of HSCs, we examined the effect of over-expression of Notch1 in the HSC-T6 cell line. After the pcDNA3.1-NICD1 was co-transfected with reporter plasmids of GLuc-pSMA, GLuc-P-COL1α1 or GLuc-P-COL1α2, respectively, into HSC-T6 for 24 h, the supernatant was collected for a luciferase reporter assay. The results revealed that the promoter activities of α-SMA, COL1α1 and COL1α2 were reduced (Figure 2).

Figure 2.

Figure 2

NICD1 suppresses the expression of myofibroblastic markers in hepatic stellate cell-T6 cells. A-C: Luciferase reporter assays for the promoter activities of α-SMA, COL1α1, COL1α2 in cells transfected with empty plasmid-pcDNA3.1(+) as a control or with pcDNA3.1-NICD1 (aP < 0.05 vs the control group, n = 8). α-SMA: α-smooth muscle actin; COL1α1: Collagen1α1.

Over-expression of Hes1 increases the expression of myofibroblastic markers in HSC-T6

To determine whether the Notch1 target gene Hes1 is involved in the activation of HSCs, the pcDNA-Hes1 plasmid was co-transfected with the reporter plasmids GLuc-pSMA, GLuc-P-COL1α1 or GLuc-P-COL1α2 into HSC-T6 cells for 24 h. The supernatant was collected for luciferase assays. The activities of GLuc-pSMA and GLuc-P-COL1α2 were higher in the pcDNA-Hes1 transfected cells than in the empty vector control cells (Figure 3A, C), while over-expression of Hes1 did not alter the activity of the COL1α1 promoter (Figure 3B). Over-expression of Hes1 also increased the expression of endogenous α-SMA, as revealed by Western blot analysis (Figure 3D). Thus, Hes1, a Notch signaling target gene, has an opposite effect on the activation of HSCs to that of the Notch1 receptor.

Figure 3.

Figure 3

Over-expression of the Notch target gene Hes1 increases the expression of α-smooth muscle actin and Collagen1α2 in hepatic stellate cell-T6 cells but has no effect on the expression of Collagen1α1. A, C, D: Luciferase reporter assays for the promoter activities of α-SMA, COL1α1 and COL1α2 in cells transfected with pcDNA-Hes1 or empty plasmid-pcDNA3.1(+) as a control (aP < 0.05, bP < 0.01 vs the control group, n = 8); B: Analysis of α-SMA and Hes1 by Western blot analysis of transfected cells. The β-actin protein served as a control (cP < 0.05 vs all the control groups). α-SMA: α-smooth muscle actin; COL1α1: Collagen1α1.

Inhibiting the function of the Hes1 transcription factor with a Hes1 ODN decoy down-regulates the expression of α-SMA and collagen1 in HSC-T6 cells

To inhibit Hes1, an ODN decoy was transfected into the HSCs. The Hes1 ODN decoy is a double-stranded DNA containing a Hes1 binding site. After the Hes1 ODN decoy was delivered into the HSC-T6 cells, the luciferase reporter activities for the pSMA and P-COL1α2 reporter constructs decreased compared with those in the control group (Scr) (Figure 4A, B). Thus, inhibiting the function of the Hes1 transcription factor in HSC-T6 cells could down-regulate the expression of α-SMA and COL1α2.

Figure 4.

Figure 4

Inhibition of Hes1 transcription factor function by a Hes1 decoy down-regulates the promoter activities of α-smooth muscle actin and Collagen1α2 in hepatic stellate cell-T6 cells. The promoter activities of α-SMA and col1α2 decreased in cells treated with a Hes1 ODN decoy compared with the control (SCR) (A, B). (aP < 0.05 vs the control and SCR groups, n = 8). α-SMA: α-smooth muscle actin; ODN: Oligodeoxynucleotide.

Notch1 target gene Hes1 is regulated by TGF/BMP signaling in HSC-T6 cells

It is well known that Notch1 can induce the expression of Hes1 directly in many mammalian cell types. To determine whether Notch1 up-regulates the expression of Hes1 in HSC-T6 cells, the GLuc-P-Hes1 and pcDNA3.1-NICD1 plasmids were co-transfected into HSC-T6 cells, and GLuc reporter analysis showed that the promoter activity of Hes1 was enhanced approximately 5.5-fold compared with the activity in cells transfected with the empty plasmid pcDNA3.1 (Figure 5B). At the protein level, pcDNA3.1-NICD1 also increased the expression of Hes1 based on Western blot analysis (Figure 5A). Next, we studied the relationship between the TGF-β/BMP signaling pathway and Hes1. To investigate whether the Notch pathway interacts with the TGF-β/BMP signaling pathway in HSC-T6 cells, a pcDNA3-CA-ALK3 (BMP signaling activin receptor-like kinase 3) expression vector was transfected into HSC-T6 cells, and the Notch target gene Hes1 and the TGF-β receptor were analyzed by Western blot. We found that over-expression of CA-ALK3 increased the expression of Hes1 approximately 2.5-fold (Figure 5C), while the expression of the TGF-β receptor was not altered (Figure 5C). We also obtained the same results using a luciferase reporter assay. When pcDNA3-CA-ALK3 and GLuc-P-Hes1 were co-transfected into HSC-T6 cells, the reporter activity increased approximately 2-fold compared with the control (empty vector pcDNA3.1). In addition, co-transfection with pcDNA3-CA-ALK3 and pcDNA3.1-NICD1 cooperatively enhanced the expression of Hes1 compared to transfection with pcDNA3-CA-ALK3 or pcDNA3.1-NICD1 alone in HSC-T6 cells (Figure 5B). Thus, CA-ALK3 enhances NICD1-mediated up-regulation of Hes1 in HSC-T6 cells. We also analyzed the effect of CA-ALK5, an antagonist of CA-ALK3, and found that it could not affect Hes1 expression by itself in HSC-T6 cells but reduced the effects of NICD1 on Hes1 expression (Figure 5D).

Figure 5.

Figure 5

Notch target gene Hes1 is regulated by the transforming growth factor-β/bone morphogenetic protein signaling pathway in hepatic stellate cell-T6 cells. A: Western blot analysis of Hes1 expression in cells transfected with pcDNA3.1-NICD1. The β-actin protein served as a control; B: Luciferase reporter assays for the Hes1 promoter in cells transfected with pcDNA3-NICD1 and/or pcDNA3-CA-ALK3 (aP < 0.05, bP < 0.01 vs all the control groups, n = 8); C: Analysis of Hes1 and TGF-β(R) by Western blot analysis of cells transfected with pcDNA3-CA-ALK3 with the β-actin protein as a control; D: Luciferase reporter assays for the Hes1 promoter in cells transfected with pcDNA3.1-NICD1 and/or pcDNA3-CA-ALK5 together (dP < 0.01 vs the control group, n = 8). TGF: Transforming growth factor.

DISCUSSION

It is well accepted that HSCs play a major role in the progression of liver fibrosis because the cells can develop into myofibroblast cells that synthesize extracellular matrix proteins[22]. Thus, a better understanding of the molecular mechanisms underlying HSC activation is an important prerequisite for developing new therapeutic modalities for liver fibrosis. TGF-β signaling has been shown to be the key event in promoting fibrogenesis in vivo and in vitro; however, the development of anti-fibrotic strategies targeting the TGF-β axis is uncertain because of the pleiotropic nature of TGF-β action[23].

Notch signaling is critical for the regulation of cell differentiation, and its aberrant activation has been implicated in human fibrosis diseases. It has ben confirmed that Notch3 may regulate the activation of HSCs, but it is unknown whether other members of the Notch family, such as Notch1, Notch2 and Notch4, play a part in activating HSCs and if so, what the underlying mechanism may be[24]. In studies of the HSC niche in the rat liver, it has been found that Notch1 is involved in the regulation of β-catenin-dependent Wnt signaling and may be a marker for activated somatic stem/progenitor cells[25,26]. Some studies have also shown that, in response to inflammatory zone 1, Notch1 signaling may play a significant role in myofibroblast differentiation during lung fibrosis[14]. Thus, we hypothesized that Notch1 signaling may play an important role in liver fibrosis.

Our present study suggests that Notch1 and its target gene, Hes1, play crucial roles in liver fibrosis. Based on the evidence described above, we focused on Notch1 and its target gene Hes1 in our study. Our findings showed that Notch1 and Hes1 mRNA expression decreased upon the activation of freshly isolated HSCs, in agreement with an earlier report[27]. To investigate the effects of the Notch1 receptor and Hes1 in HSC-T6 cells, we over-expressed Notch1 and Hes1 in HSC-T6 cells and found that Notch1 inhibited α-SMA, COL1α1 and COL1α2 promoter activities, while Hes1 enhanced the α-SMA and COL1α2 promoter activities. These findings suggest that the Notch1 receptor, as an upstream gene in the Notch signaling pathway, has pleiotropic effects not displayed by its downstream target, the Hes1 transcription factor. Hes1 is a bHLH transcription factor, and Hes1 homodimers auto-inhibit their own transcription by directly binding to the N-box in the Hes1 promoter. This negative feedback leads to the rapid disappearance of the extremely unstable Hes1 protein and allows a new round of expression[16]. This negative feedback may keep expression of the Hes1 protein in a reasonable range when pcDNA3.1-NICD1 is transfected into HSCs. On the other hand, Hes1 protein expression will be much higher when pcDNA3.1-Hes1 is transfected into HSCs. Because of the pleiotropic effects of Notch1 and the negative feedback of Hes1, Notch1 may keep the Hes1 protein at a reasonable level and restrain the promoter activities of α-SMA, COL1α1 and COL1α2 in HSCs, while over-expression of Hes1 may enhance the promoter activities of α-SMA and COL1α2.

We have shown that Hes1 participated in the activation of HSCs. Thus, another important question is which factors affect Hes1 expression in HSCs. Previous studies have suggested that Notch signaling may interact with TGF-β/BMP signaling and regulate the expression of Hes1 in many cell types[16]. To determine whether a similar mechanism exists in HSC-T6 cells, we analyzed the effect of CA-ALK3 and CA-ALK5. CA-ALK3 alone increased the expression of Hes1, and more importantly, CA-ALK3 strengthened the NICD1-mediated effects on Hes1 expression in HSC-T6 cells. CA-ALK5, on the other hand, could not alone affect Hes1 expression in HSC-T6 cells, but it did reduce the effects of NICD1 on the expression of Hes1. Earlier studies suggested a mechanism in which NICD1 binds phosphorylated SMAD1/5/8 (P-SMAD1/5/8) and forms a NICD1-P-SMAD1/5/8 complex, which then migrates into the nucleus, causing the activation of the Hes1 promoter in HSC-T6 cells[28,29]. CA-ALK5 can increase SMAD2/3 phosphorylation (P-SMAD2/3) and attenuate the levels of P-SMAD1/5/8 through SMAD6, ultimately leading to a significant reduction in the NICD1-P-SMAD1/5/8 complex and inhibition of Hes1 promoter activity[16]. Thus, our results demonstrate that TGF/BMP signaling interacts with Notch1 to regulate Hes1 expression in HSC-T6 cells. Clearly, the role of Notch1 and TGF-β1/BMP signaling in the regulation of the Hes1 promoter should be further investigated.

In conclusion, Notch signaling appears to interact with TGF-β/BMP signaling and co-regulates Hes1 expression in HSCs. Notch1 may keep Hes1 protein expression at a reasonable level through Hes1 auto-negative feedback, allowing Notch1 to repress the expression of α-SMA and COL1α2. This repression is consistent with the effect of capturing Hes1 using a Hes1 ODN decoy, which could, nonetheless, reduce the effects of NICD1 on Hes1 expression. Over-expression of Hes1 via transfection, which bypasses the negative feedback, enhances the promoter activities of α-SMA and COL1α2. This may provide an anti-fibrotic strategy against hepatic fibrosis. Further investigations of the molecular mechanisms of Hes1-mediated regulation of α-SMA and COL1α2 should provide additional support for such an approach.

ACKNOWLEDGMENTS

We are grateful to the Institute of Molecular Biology of China, Three Gorges University, for providing us with an experimental platform, and thank Li-Li Zou for technical assistance. We thank Dr. Yun-Bo Shi of the American NIH for his helpful suggestions on the manuscript.

COMMENTS

Background

It is well known that a better understanding of the molecular mechanisms underlying hepatic stellate cell (HSC) activation is an important prerequisite for developing new therapeutic modalities for liver fibrosis. The Notch signaling pathway is critical for the regulation of cell differentiation. Recently, Notch has been implicated in human liver fibrosis diseases. It has been confirmed that Notch3 may regulate the activation of HSCs, but it is unknown whether other members of the Notch family, such as Notch1, Notch2 and Notch4, play a part in HSC activation and what the underlying mechanisms might be.

Research frontiers

During hematopoiesis and immune development, Notch is critical for T/B lineage specification and for the generation of splenic marginal zone B cells. Earlier research mainly focused on the interconnections between Notch and hematopoiesis or immune system-related molecules, aiming to find a preferable method to modulate hematopoiesis or treat immune disorders. In our paper, we explored whether Notch signaling has a function in regulating HSC activation.

Innovations and breakthroughs

This study illuminates the role of Notch1 and its target gene Hes1 in HSC activation. Furthermore, we found that Notch signaling appears to interact with transforming growth factor-β (TGF-β)/bone morphogenetic protein (BMP) signaling and co-regulates Hes1 expression in HSCs. This finding indicates that Notch1 and its target gene Hes1 may contribute to liver fibrosis by regulating HSC activation.

Applications

This study demonstrated that over-expression of Notch1 or selective interruption of Hes1 decreases the expression of myofibroblastic markers in rat hepatic stellate cells, which provides a potential novel therapeutic target for liver fibrosis.

Peer review

The submitted manuscript entitled, “Hes1, an important gene for activation of hepatic stellate cells, is regulated by Notch1 and TGF-β/BMP signaling” presents a very interesting study. The finding highlights the crosstalk between Notch and TGF-β/BMP signaling modules in the regulation of Hes1 in hepatic stellate cells towards the understanding of anti-fibrotic mechanism. Overall, the study is very well conceived, designed and executed as well as well written.

Footnotes

Supported by National Natural Science Foundation of China, No. 81170412, No. 81070348 and No. 81200307; Health Department of Hubei Province of China, No. JX6C-26.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Peer-review started: April 24, 2014

First decision: May 29, 2014

Article in press: July 16, 2014

P- Reviewer: Higuera-de la Tijera MF, Kovacs SJ, Parvez MK S- Editor: Qi Y L- Editor: Wang TQ E- Editor: Liu XM

References

  • 1.Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev. 2008;88:125–172. doi: 10.1152/physrev.00013.2007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Wells RG. The role of matrix stiffness in hepatic stellate cell activation and liver fibrosis. J Clin Gastroenterol. 2005;39:S158–S161. doi: 10.1097/01.mcg.0000155516.02468.0f. [DOI] [PubMed] [Google Scholar]
  • 3.Bataller R, Brenner DA. Hepatic stellate cells as a target for the treatment of liver fibrosis. Semin Liver Dis. 2001;21:437–451. doi: 10.1055/s-2001-17558. [DOI] [PubMed] [Google Scholar]
  • 4.Purps O, Lahme B, Gressner AM, Meindl-Beinker NM, Dooley S. Loss of TGF-beta dependent growth control during HSC transdifferentiation. Biochem Biophys Res Commun. 2007;353:841–847. doi: 10.1016/j.bbrc.2006.12.125. [DOI] [PubMed] [Google Scholar]
  • 5.Choi SS, Diehl AM. Epithelial-to-mesenchymal transitions in the liver. Hepatology. 2009;50:2007–2013. doi: 10.1002/hep.23196. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Sugiyama D, Kulkeaw K, Mizuochi C. TGF-beta-1 up-regulates extra-cellular matrix production in mouse hepatoblasts. Mech Dev. 2013;130:195–206. doi: 10.1016/j.mod.2012.09.003. [DOI] [PubMed] [Google Scholar]
  • 7.Weiskirchen R, Meurer SK, Gressner OA, Herrmann J, Borkham-Kamphorst E, Gressner AM. BMP-7 as antagonist of organ fibrosis. Front Biosci (Landmark Ed) 2009;14:4992–5012. doi: 10.2741/3583. [DOI] [PubMed] [Google Scholar]
  • 8.Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: cell fate control and signal integration in development. Science. 1999;284:770–776. doi: 10.1126/science.284.5415.770. [DOI] [PubMed] [Google Scholar]
  • 9.Iso T, Kedes L, Hamamori Y. HES and HERP families: multiple effectors of the Notch signaling pathway. J Cell Physiol. 2003;194:237–255. doi: 10.1002/jcp.10208. [DOI] [PubMed] [Google Scholar]
  • 10.Kageyama R, Ohtsuka T, Tomita K. The bHLH gene Hes1 regulates differentiation of multiple cell types. Mol Cells. 2000;10:1–7. doi: 10.1007/s10059-000-0001-0. [DOI] [PubMed] [Google Scholar]
  • 11.Harman BC, Jenkinson EJ, Anderson G. Entry into the thymic microenvironment triggers Notch activation in the earliest migrant T cell progenitors. J Immunol. 2003;170:1299–1303. doi: 10.4049/jimmunol.170.3.1299. [DOI] [PubMed] [Google Scholar]
  • 12.Maillard I, Adler SH, Pear WS. Notch and the immune system. Immunity. 2003;19:781–791. doi: 10.1016/s1074-7613(03)00325-x. [DOI] [PubMed] [Google Scholar]
  • 13.Bielesz B, Sirin Y, Si H, Niranjan T, Gruenwald A, Ahn S, Kato H, Pullman J, Gessler M, Haase VH, et al. Epithelial Notch signaling regulates interstitial fibrosis development in the kidneys of mice and humans. J Clin Invest. 2010;120:4040–4054. doi: 10.1172/JCI43025. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Liu T, Hu B, Choi YY, Chung M, Ullenbruch M, Yu H, Lowe JB, Phan SH. Notch1 signaling in FIZZ1 induction of myofibroblast differentiation. Am J Pathol. 2009;174:1745–1755. doi: 10.2353/ajpath.2009.080618. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Fu Y, Chang A, Chang L, Niessen K, Eapen S, Setiadi A, Karsan A. Differential regulation of transforming growth factor beta signaling pathways by Notch in human endothelial cells. J Biol Chem. 2009;284:19452–19462. doi: 10.1074/jbc.M109.011833. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Beets K, Huylebroeck D, Moya IM, Umans L, Zwijsen A. Robustness in angiogenesis: notch and BMP shaping waves. Trends Genet. 2013;29:140–149. doi: 10.1016/j.tig.2012.11.008. [DOI] [PubMed] [Google Scholar]
  • 17.Nyhan KC, Faherty N, Murray G, Cooey LB, Godson C, Crean JK, Brazil DP. Jagged/Notch signalling is required for a subset of TGFβ1 responses in human kidney epithelial cells. Biochim Biophys Acta. 2010;1803:1386–1395. doi: 10.1016/j.bbamcr.2010.09.001. [DOI] [PubMed] [Google Scholar]
  • 18.Dees C, Zerr P, Tomcik M, Beyer C, Horn A, Akhmetshina A, Palumbo K, Reich N, Zwerina J, Sticherling M, et al. Inhibition of Notch signaling prevents experimental fibrosis and induces regression of established fibrosis. Arthritis Rheum. 2011;63:1396–1404. doi: 10.1002/art.30254. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Eda H, Kulig KM, Steiner TA, Shimada H, Patel K, Park E, Kim ES, Borenstein JT, Neville CM, Keller BT. A nanofiber membrane maintains the quiescent phenotype of hepatic stellate cells. Dig Dis Sci. 2012;57:1152–1162. doi: 10.1007/s10620-012-2084-9. [DOI] [PubMed] [Google Scholar]
  • 20.Fujii M, Takeda K, Imamura T, Aoki H, Sampath TK, Enomoto S, Kawabata M, Kato M, Ichijo H, Miyazono K. Roles of bone morphogenetic protein type I receptors and Smad proteins in osteoblast and chondroblast differentiation. Mol Biol Cell. 1999;10:3801–3813. doi: 10.1091/mbc.10.11.3801. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Nakao A, Imamura T, Souchelnytskyi S, Kawabata M, Ishisaki A, Oeda E, Tamaki K, Hanai J, Heldin CH, Miyazono K, et al. TGF-beta receptor-mediated signalling through Smad2, Smad3 and Smad4. EMBO J. 1997;16:5353–5362. doi: 10.1093/emboj/16.17.5353. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Tsukada S, Parsons CJ, Rippe RA. Mechanisms of liver fibrosis. Clin Chim Acta. 2006;364:33–60. doi: 10.1016/j.cca.2005.06.014. [DOI] [PubMed] [Google Scholar]
  • 23.Hernandez-Gea V, Friedman SL. Pathogenesis of liver fibrosis. Annu Rev Pathol. 2011;6:425–456. doi: 10.1146/annurev-pathol-011110-130246. [DOI] [PubMed] [Google Scholar]
  • 24.Chen YX, Weng ZH, Zhang SL. Notch3 regulates the activation of hepatic stellate cells. World J Gastroenterol. 2012;18:1397–1403. doi: 10.3748/wjg.v18.i12.1397. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Sawitza I, Kordes C, Reister S, Häussinger D. The niche of stellate cells within rat liver. Hepatology. 2009;50:1617–1624. doi: 10.1002/hep.23184. [DOI] [PubMed] [Google Scholar]
  • 26.Reister S, Kordes C, Sawitza I, Häussinger D. The epigenetic regulation of stem cell factors in hepatic stellate cells. Stem Cells Dev. 2011;20:1687–1699. doi: 10.1089/scd.2010.0418. [DOI] [PubMed] [Google Scholar]
  • 27.Xie G, Karaca G, Swiderska-Syn M, Michelotti GA, Krüger L, Chen Y, Premont RT, Choi SS, Diehl AM. Cross-talk between Notch and Hedgehog regulates hepatic stellate cell fate in mice. Hepatology. 2013;58:1801–1813. doi: 10.1002/hep.26511. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Larrivée B, Prahst C, Gordon E, del Toro R, Mathivet T, Duarte A, Simons M, Eichmann A. ALK1 signaling inhibits angiogenesis by cooperating with the Notch pathway. Dev Cell. 2012;22:489–500. doi: 10.1016/j.devcel.2012.02.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Moya IM, Umans L, Maas E, Pereira PN, Beets K, Francis A, Sents W, Robertson EJ, Mummery CL, Huylebroeck D, et al. Stalk cell phenotype depends on integration of Notch and Smad1/5 signaling cascades. Dev Cell. 2012;22:501–514. doi: 10.1016/j.devcel.2012.01.007. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from World Journal of Gastroenterology : WJG are provided here courtesy of Baishideng Publishing Group Inc

RESOURCES